- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 35/02 - Antineoplastic agents specific for leukemia
Patent holdings for IPC class A61P 35/02
Total number of patents in this class: 9277
10-year publication summary
|
208
|
234
|
517
|
634
|
739
|
796
|
827
|
760
|
743
|
462
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Novartis AG | 10726 |
134 |
| Immatics Biotechnologies GmbH | 1153 |
99 |
| Dana-Farber Cancer Institute, Inc. | 2577 |
92 |
| Daiichi Sankyo Company, Limited | 1886 |
83 |
| Toray Industries, Inc. | 6974 |
74 |
| Celgene Corporation | 1397 |
71 |
| Memorial Sloan-Kettering Cancer Center | 1940 |
70 |
| The Regents of the University of California | 20035 |
63 |
| Genentech, Inc. | 3988 |
60 |
| Board of Regents, The University of Texas System | 5841 |
59 |
| Takeda Pharmaceutical Company Limited | 2707 |
57 |
| Janssen Pharmaceutica N.V. | 3381 |
50 |
| Janssen Biotech, Inc. | 1552 |
49 |
| Inserm (institut National de La Sante et de La Recherche Medicale) | 3364 |
48 |
| F. Hoffmann-La Roche AG | 7942 |
45 |
| Shanghai Institute of Materia Medica, Chinese Academy of Sciences | 833 |
43 |
| Bristol-myers Squibb Company | 4867 |
40 |
| King Faisal University | 919 |
40 |
| Institut National de La Sante et de La Recherche Medicale (inserm) | 2880 |
39 |
| University Health Network | 1047 |
39 |
| Other owners | 8022 |